ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
